If you have Mycobacterium avium complex (MAC) lung disease, your doctor may suggest treatment with Arikayce. It’s a prescription drug used together with other drugs to treat MAC lung disease that’s ...

--Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced positive topline results from its Phase 3 ...

BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

—Additional Data from ARISE Study Evaluating the Impact of ARIKAYCE on Microbiologic Outcomes in Patients with Newly Diagnosed or Recurrent MAC Lung Disease to be Presented as Late-Breaker— —Data to ...

ARIKAYCE is delivered by a novel inhalation device, the Lamira ® Nebulizer System, developed by PARI. Lamira ® is a quiet, portable nebulizer that enables efficient aerosolization of liquid ...

Arikayce (amikacin liposome) is a brand-name inhalation suspension that’s prescribed to treat a certain bacterial lung infection. As with other drugs, Arikayce can cause side effects, such as cough, ...

ARIKAYCE is delivered by a novel inhalation device, the Lamira ® Nebulizer System, developed by PARI. Lamira ® is a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a ...

ARIKAYCE is delivered by a novel inhalation device, the Lamira® Nebulizer System, developed by PARI. Lamira® is a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a ...

—QOL-B Respiratory Domain Shown to Work Effectively as Patient-Reported Outcome Tool in Patients with MAC Lung Disease; to be Proposed to FDA as Primary Endpoint in ENCORE with No Modifications— ...